HC Wainwright cut shares of Acer Therapeutics (NASDAQ:ACER – Free Report) from a buy rating to a neutral rating in a research report released on Tuesday morning, Marketbeat reports. HC Wainwright also issued estimates for Acer Therapeutics’ Q3 2023 earnings at ($0.12) EPS, Q4 2023 earnings at ($0.06) EPS and FY2024 earnings at $0.00 EPS. […]
ACER THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acer Therapeutics Inc. tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws.
NEW YORK, Sept. 6, 2023 /PRNewswire/ Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or.
Roth Capital reaffirmed their neutral rating on shares of Acer Therapeutics (NASDAQ:ACER – Free Report) in a report issued on Friday, Benzinga reports. They currently have a $1.50 price target on the biopharmaceutical company’s stock. Separately, Roth Mkm cut Acer Therapeutics from a buy rating to a neutral rating and set a $1.50 target price […]